Malignancy and myositis: novel autoantibodies and new insights

Selva-O’Callaghan, Albert; Trallero-Araguás, Ernesto; Grau-Junyent, Josep María; Labrador‐Horrillo, Moisés

doi:10.1097/bor.0b013e32833f1075

Cited by 94 publications

(55 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The clinical manifestations of this reactivity involve high prevalences in dermatomyositis, as reported by Targoff et al, but with a high specificity the occurrence of this MSA correlates with a risk of malignancies as (Kaji et al, 2007). This observation was statistically underlined when Selva O´Canaghan et al performed a meta analysis for anti TIF 1 gamma antibodies and predictive values for malignancies (Selva-O'Callaghan et al, 2010) and found that anti p155/TIF1 y antibodies have a 70 % sensitivity and a 90 % specificity to detect occult malignancies in DM. The TIF1 gamma protein as described by Venturini et al shows a strong silencing activity towards gentic promoter sequences.…”

Section: Tif1 Gammamentioning

confidence: 84%

Serological Aspects of Myositis

Schulte-Pelkum¹

2011

Idiopathic Inflammatory Myopathies - Recent Developments

View full text Add to dashboard Cite

Section: Tif1 Gammamentioning

confidence: 84%

Serological Aspects of Myositis

Schulte-Pelkum¹

2011

Idiopathic Inflammatory Myopathies - Recent Developments

View full text Add to dashboard Cite

“…14 In contrast, in adults, reports of malignancy in association with adult dermatomyositis and, to a much lesser extent, polymyositis, have ranged from 10% to 42% of cases. 5,8,14,15 In 618 adults with adult dermatomyositis, there was a strong association with ovarian tumors (most of them adenocarcinomas) followed by lung cancer, gastrointestinal cancers, and non-Hodgkin lymphoma. 8 In adults with myositis, but not children (as in this case), myositisspecific antibody to p155/140 seemed to be a prognostic factor for malignancy, and ethnicity strongly influenced the type of malignancy found.…”

Section: Discussionmentioning

confidence: 99%

Ovarian Teratoma Mimicking Features of Juvenile Dermatomyositis in a Child

2011

View full text Add to dashboard Cite

An 8-year-old girl complained for 4 months of right arm pain, weakness in both legs, difficulty in arising from a seated or squatting position, and 1 month of pain in her hips, ankles, and knees. On physical examination, she had weak neck flexors, weak proximal and abdominal muscles, and an assisted Gower maneuver; both knees and ankles were painful. Erythematous macules on her elbows, knees, and medial ankles were present without heliotrope rash or dilated eyelid capillaries. She had nail-fold erythema and decreased numbers of nail-fold capillary end-row loops (ERLs) . MRI of her thigh muscles revealed serpiginous increased T-2 signals consistent with inflammation and a complex round mass in the left pelvis. A muscle biopsy did not indicate juvenile dermatomyositis. Pelvic ultrasound confirmed a solid mass of the left ovary consistent with a mature teratoma. After surgical removal of the teratoma, the myositis, synovitis, and cutaneous findings resolved over 4 months without further therapy.

show abstract

“…Myositisoverlap syndromes also present with myalgias and weakness in conjunction with other rheumatologic diseases such as rheumatoid arthritis or systemic lupus erythematosus [Gherardi, 2011]. Malignancy must also be considered in patients presenting with weakness and myalgias because the incidence of new cancer is higher in patients with IIM [Selva-O'Callaghan et al 2010;Zahr and Baer, 2011]. Drug-induced or toxic myopathies can present with acute or subacute muscle weakness, myalgia, elevated CK levels and/or myoglobinuria [Valiyil and Christopher-Stine, 2010].…”

Section: Myositis Mimics/differential Diagnosismentioning

confidence: 99%

Diagnosis and treatment of inflammatory myopathy: issues and management

Castro¹,

Gourley²

2011

Therapeutic Advances in Musculoskeletal

View full text Add to dashboard Cite

Abstract:The idiopathic inflammatory myopathies include polymyositis (PM), dermatomyositis (DM) and inclusion body myositis (IBM). The specific etiologies of these muscle diseases are not well known and are thought to involve components of the humoral and cellular immune system as well as other nonimmune factors. Diagnosing these myopathies involves a laboratory evaluation, imaging studies, multidisciplinary consultations, histologic examination and potentially genetic studies. Despite all that we currently know about inflammatory muscle disease with these studies, we find that our current concept of muscle disease is changing. In the cases of immune-mediated necrotizing myopathy and inclusion body myositis, the concept of inflammation needs to be rethought. Moreover, the classification schemes for these idiopathic myopathies may need updating to include current research findings that relate to pathogenesis. With ongoing discoveries, classification and appropriate treatment is becoming increasingly challenging. This paper discusses the inflammatory myopathies, the challenges to diagnosis, classification controversies and potential treatment options.

show abstract

Malignancy and myositis: novel autoantibodies and new insights

Cited by 94 publications

References 37 publications

Serological Aspects of Myositis

Serological Aspects of Myositis

Ovarian Teratoma Mimicking Features of Juvenile Dermatomyositis in a Child

Diagnosis and treatment of inflammatory myopathy: issues and management

Contact Info

Product

Resources

About